Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 3/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5663251 | 0.89 | PTPN2 (0.62) | NAMPTALOX12PTPN2PTPN1PTPN6 | |
| SCHEMBL2878255 | 0.88 | NAMPT (0.57) | NAMPTALOX12PTPN2PTPN1PTPN6 | |
| SCHEMBL16835018 | 0.87 | NAMPT (0.53) | NAMPTALOX12PTPN2PTPN1PTPN6 | |
| SCHEMBL14587425 | 0.87 | GPR119 (0.51) | NAMPTALOX12PTPN2PTPN1PTPN6 | |
| SCHEMBL3986594 | 0.85 | NAMPT (0.51) | NAMPTALOX12PTPN2PTPN1PTPN6 | |
| SCHEMBL5514009 | 0.85 | DRD2 (0.56) | NAMPTALOX12DRD2 | |
| SCHEMBL16835038 | 0.85 | NAMPT (0.54) | NAMPTALOX12PTPN2PTPN1PTPN6 | |
| SCHEMBL16835012 | 0.84 | DRD4 (0.55) | NPC1RAB9ADRD4DRD2DRD3 | |
| SCHEMBL16834973 | 0.84 | ALOX12 (0.59) | NAMPTALOX12JAK2JAK3PTK2 | |
| SCHEMBL328235 | 0.84 | RAB9A (0.50) | NAMPTALOX12PTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083601-B1 | PIPERIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-09-09 | — | — | EP | disclosed |
| US-9981942-B2 | Piperidine derivatives having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2018-05-29 | — | — | US | disclosed |
| US-20170001978-A1 | PIPERIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-01-05 | — | — | US | disclosed |
| EP-3083601-A1 | PIPERIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015091939-A1 | PIPERIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-06-25 | — | — | WO | disclosed |
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MARZABADI MOHAMMAD R | 2007-02-22 | — | — | US | disclosed |
| US-7067534-B1 | Substituted anilinic piperidines as MCH selective antagonists | H. LUNDBECK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| EP-1411942-A4 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMA CORP (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1411942-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | Synaptic Pharmaceutical Corporation (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6727264-B1 | MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
| WO-2003004027-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MCHR1, MCHR2, MC1R | NAMPT 1815/4885ALOX12 2297/4885PTPN2 815/4885 |
| US-20170001978-A1 | PIPERIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, OPRM1, OPRK1 | NAMPT 3172/4885ALOX12 976/4885PTPN2 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.